drugset / Trial / NCT00468117
Efficacy of Islet After Kidney Transplantation
Phase 3
Completed
24 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelTreatment
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic (T1D) kidney transplant recipients.
Timeline
- Start
- 2007-01
- Primary completion
- 2015-07
- Completion
- 2017-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogenic human purified pancreatic islets | Cell therapy | 200 ml | Intravenous |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | — |
| Background | Basiliximab | Monoclonal antibody | — | — |
| Background | Daclizumab | Monoclonal antibody | — | — |
| Background | Etanercept | Protein / enzyme biologic | — | — |